OliX Pharmaceuticals, Inc

KOSDAQ:A226950 Stock Report

Market Cap: ₩310.3b

OliX Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

OliX Pharmaceuticals's earnings have been declining at an average annual rate of -8.1%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 48.8% per year.

Key information

-8.1%

Earnings growth rate

-5.2%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate48.8%
Return on equity-150.6%
Net Margin-156.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

Dec 07
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump

OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

Nov 15
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt

OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Oct 09
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

Aug 22
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22
We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25
It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13
OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17
Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Revenue & Expenses Breakdown

How OliX Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A226950 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416,138-25,30214,23520,229
30 Jun 2417,899-19,72114,28917,560
31 Mar 2415,576-19,00314,84818,600
31 Dec 2317,064-19,10214,17818,478
30 Sep 237,251-27,35614,71916,504
30 Jun 239,663-27,71214,02618,120
31 Mar 239,249-26,29112,72718,174
31 Dec 229,320-25,72012,34617,379
30 Sep 229,507-26,77012,15117,251
30 Jun 225,873-30,66412,35617,857
31 Mar 225,007-28,28612,02116,833
31 Dec 213,674-28,61311,48814,992
30 Sep 214,043-30,16311,13415,017
30 Jun 214,148-25,18110,41212,125
31 Mar 213,288-24,7419,57710,957
31 Dec 202,474-19,3858,2279,478
30 Sep 201,519-16,8717,24710,263
30 Jun 20958-16,1476,9869,824
31 Mar 201,196-14,8856,5629,523
31 Dec 191,130-14,3536,6658,973
30 Sep 191,039-10,9735,5406,932
30 Jun 19758-9,3994,5886,096
31 Mar 19418-8,1703,9604,977
31 Dec 18302-7,7423,2005,082
31 Dec 17244-5,1642,0483,334

Quality Earnings: A226950 is currently unprofitable.

Growing Profit Margin: A226950 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A226950 is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare A226950's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A226950 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A226950 has a negative Return on Equity (-150.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 00:25
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OliX Pharmaceuticals, Inc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Wan KuNH Investment & Securities Co., Ltd.